|
MechanismCLDN18.2 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Hebo Pharmaceutical (Suzhou) Co., Ltd.
0 Patents (Medical) associated with Hebo Pharmaceutical (Suzhou) Co., Ltd.
100 Deals associated with Hebo Pharmaceutical (Suzhou) Co., Ltd.
100 Translational Medicine associated with Hebo Pharmaceutical (Suzhou) Co., Ltd.